# Index

<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>abstracting impairment</td>
<td>179</td>
</tr>
<tr>
<td>academic achievement</td>
<td>179–80</td>
</tr>
<tr>
<td>acquired immune deficiency syndrome (AIDS)</td>
<td>169</td>
</tr>
<tr>
<td>acquired tolerance</td>
<td>2</td>
</tr>
<tr>
<td>acyclovir</td>
<td>295</td>
</tr>
<tr>
<td>adolescents 278, 280, 282; see also pediatric transplantation</td>
<td>264–5</td>
</tr>
<tr>
<td>adrenaline</td>
<td>264–5</td>
</tr>
<tr>
<td>adrenocorticotropic hormone (ACTH)</td>
<td>260</td>
</tr>
<tr>
<td>Affect Balance Scale (ABS)</td>
<td>110</td>
</tr>
<tr>
<td>aging population</td>
<td>146</td>
</tr>
<tr>
<td>albumin</td>
<td>188</td>
</tr>
<tr>
<td>alcohol abuse</td>
<td>169–70</td>
</tr>
<tr>
<td>cognitive impairment and end stage organ disease epidemiology and 214–16</td>
<td></td>
</tr>
<tr>
<td>post-transplantation issues 222–9</td>
<td></td>
</tr>
<tr>
<td>alcohol relapse 223–4, 228</td>
<td></td>
</tr>
<tr>
<td>alcohol-related morbidity and mortality 228–9, 230–1</td>
<td></td>
</tr>
<tr>
<td>heart transplantation 230–1</td>
<td></td>
</tr>
<tr>
<td>monitoring alcohol use 224–6</td>
<td></td>
</tr>
<tr>
<td>outcome and survival 222–3</td>
<td></td>
</tr>
<tr>
<td>predictors of alcohol use 222–8</td>
<td></td>
</tr>
<tr>
<td>pretransplant survival and 216–17</td>
<td></td>
</tr>
<tr>
<td>transplantation patient selection issues 217–22</td>
<td></td>
</tr>
<tr>
<td>ethics and policies 217–18</td>
<td></td>
</tr>
<tr>
<td>heart transplantation 220</td>
<td></td>
</tr>
<tr>
<td>liver transplantation 218–20</td>
<td></td>
</tr>
<tr>
<td>selection instruments 220–2</td>
<td></td>
</tr>
<tr>
<td>sobriety requirements 218–19</td>
<td></td>
</tr>
<tr>
<td>Alcoholism Prognosis Scale (APS) 221</td>
<td></td>
</tr>
<tr>
<td>alprazolam</td>
<td>268</td>
</tr>
<tr>
<td>Americans with Disabilities Act (ADA)</td>
<td>119–20</td>
</tr>
<tr>
<td>anxiety disorders</td>
<td>266</td>
</tr>
<tr>
<td>attention 176</td>
<td></td>
</tr>
<tr>
<td>attention deficit disorder with hyperactivity</td>
<td>170</td>
</tr>
<tr>
<td>azathioprine 6, 9, 204, 292, 294, 299</td>
<td></td>
</tr>
<tr>
<td>B lymphocytes</td>
<td>256</td>
</tr>
<tr>
<td>Beck Depression Inventory (BDI) 36, 110</td>
<td></td>
</tr>
<tr>
<td>Benton Visual Retention Test 167</td>
<td></td>
</tr>
<tr>
<td>benzodiazepines 170, 268</td>
<td></td>
</tr>
<tr>
<td>beta-blockers 189</td>
<td></td>
</tr>
<tr>
<td>blood donor motivation 45–6</td>
<td></td>
</tr>
<tr>
<td>bone marrow donation</td>
<td></td>
</tr>
<tr>
<td>donor ambivalence 50</td>
<td></td>
</tr>
<tr>
<td>donor decision-making 47–8</td>
<td></td>
</tr>
<tr>
<td>donor motives 45–6</td>
<td></td>
</tr>
<tr>
<td>ethical issues 246, 277</td>
<td></td>
</tr>
<tr>
<td>outcomes 61–2</td>
<td></td>
</tr>
<tr>
<td>bone marrow transplantation 3, 15–16</td>
<td></td>
</tr>
<tr>
<td>pediatric patients 281</td>
<td></td>
</tr>
<tr>
<td>quality of life studies 104–8</td>
<td></td>
</tr>
<tr>
<td>comparisons with healthy samples 119–20</td>
<td></td>
</tr>
<tr>
<td>comparisons with other similarly ill samples 116–19</td>
<td></td>
</tr>
<tr>
<td>methodologic issues 120–1</td>
<td></td>
</tr>
<tr>
<td>pre- to post-transplantation improvement 111–15</td>
<td></td>
</tr>
<tr>
<td>brain death 241–2</td>
<td></td>
</tr>
<tr>
<td>brequinar sodium (BQR) 292–3, 294–5</td>
<td></td>
</tr>
<tr>
<td>bromocriptine 267</td>
<td></td>
</tr>
<tr>
<td>Bruce Protocol Exercise Stress test 153</td>
<td></td>
</tr>
<tr>
<td>bupropion 269</td>
<td></td>
</tr>
<tr>
<td>α-butyrophophenone 268</td>
<td></td>
</tr>
<tr>
<td>calcitonin gene-related peptide (CGRP) 262</td>
<td></td>
</tr>
<tr>
<td>calcium channel blockers 200</td>
<td></td>
</tr>
<tr>
<td>antidepressants 268–9</td>
<td></td>
</tr>
<tr>
<td>selective serotonin reuptake inhibitors (SSRIs) 188, 268–9</td>
<td></td>
</tr>
<tr>
<td>tricyclic 188,193, 268</td>
<td></td>
</tr>
<tr>
<td>antilymphocyte globulin (ALG) 6</td>
<td></td>
</tr>
<tr>
<td>anxiety disorders</td>
<td></td>
</tr>
<tr>
<td>attention 176</td>
<td></td>
</tr>
<tr>
<td>attention deficit disorder with hyperactivity</td>
<td>170</td>
</tr>
<tr>
<td>azathioprine 6, 9, 204, 292, 294, 299</td>
<td></td>
</tr>
<tr>
<td>B lymphocytes</td>
<td>256</td>
</tr>
<tr>
<td>Beck Depression Inventory (BDI) 36, 110</td>
<td></td>
</tr>
<tr>
<td>Benton Visual Retention Test 167</td>
<td></td>
</tr>
<tr>
<td>benzodiazepines 170, 268</td>
<td></td>
</tr>
<tr>
<td>beta-blockers 189</td>
<td></td>
</tr>
<tr>
<td>blood donor motivation 45–6</td>
<td></td>
</tr>
<tr>
<td>bone marrow donation</td>
<td></td>
</tr>
<tr>
<td>donor ambivalence 50</td>
<td></td>
</tr>
<tr>
<td>donor decision-making 47–8</td>
<td></td>
</tr>
<tr>
<td>donor motives 45–6</td>
<td></td>
</tr>
<tr>
<td>ethical issues 246, 277</td>
<td></td>
</tr>
<tr>
<td>outcomes 61–2</td>
<td></td>
</tr>
<tr>
<td>bone marrow transplantation 3, 15–16</td>
<td></td>
</tr>
<tr>
<td>pediatric patients 281</td>
<td></td>
</tr>
<tr>
<td>quality of life studies 104–8</td>
<td></td>
</tr>
<tr>
<td>comparisons with healthy samples 119–20</td>
<td></td>
</tr>
<tr>
<td>comparisons with other similarly ill samples 116–19</td>
<td></td>
</tr>
<tr>
<td>methodologic issues 120–1</td>
<td></td>
</tr>
<tr>
<td>pre-to post-transplantation improvement 111–15</td>
<td></td>
</tr>
<tr>
<td>brain death 241–2</td>
<td></td>
</tr>
<tr>
<td>brequinar sodium (BQR) 292–3, 294–5</td>
<td></td>
</tr>
<tr>
<td>bromocriptine 267</td>
<td></td>
</tr>
<tr>
<td>Bruce Protocol Exercise Stress test 153</td>
<td></td>
</tr>
<tr>
<td>bupropion 269</td>
<td></td>
</tr>
<tr>
<td>α-butyrophophenone 268</td>
<td></td>
</tr>
<tr>
<td>calcitonin gene-related peptide (CGRP) 262</td>
<td></td>
</tr>
<tr>
<td>calcium channel blockers 200</td>
<td></td>
</tr>
</tbody>
</table>
California Verbal Learning Test 167
Campbell QOL items 110
capsaicin 262
carbamazepine (CBZ) 193, 200
carbohydrate-deficient transferrin (CDT) 225–6
cardiac transplantation see heart transplantation
cardiomyopathy, alcoholic 215, 216, 217, 220, 230
catecholamines 264
cell-mediated immunity 7–9
celcept 204–5
cephalexin 207
cerebral cortex, functional organization 172–4
chemokines 265
chimerism 11–13, 14, 15, 287, 299–300
augmentation of 11–13
microchimerism 10
ciprofloxacin 207–8
cirrhosis see liver transplantation, alcoholic cirrhosis
cisapride 193
clomipramine 268
clonazepam 204
clostrimazole 202
codine 193
cognitive capacity 172
cognitive deficit 37, 164–5
abstracting 179
academic achievement 179–80
alcohol/drug abuse and 169–70
assessment 165, 166–71
cognition in relation to psychopathology 168–71
comprehensive assessment 166–7
computer interactive evaluation 180–1
ecologically valid assessment 180
modality-specific evaluation 187–8
screening 166
attention 176
concentration 176
development and 182
iatrogenic effects 170–1
intelligence 175–6
language 177–8
memory 177
motivation and 171
neurologic disease and 170
perception 178–9
physical fitness and 171
psychomotor integration 179
neuroleptic 172
concentration 176
cognitive style 172
cognitive capacity 172
continual attention 176
corticosteroids 170, 203–4
cortisol 266
crystallized intelligence 176
CTLA4-Ig 9
cyclophosphamide 263, 299
cyclosporine 6, 9, 158, 170, 193, 267, 287, 293, 294, 299
drug interactions 200
neuropsychiatric issues 196–200
cytochrome P450 188, 189, 192–5
cytokines 256–7, 260
cytomegalovirus (CMV) 206
death, criteria for 239, 241–2
deception 171
declarative memory 177
dementia 169
dendritic cells (DCs) 10, 258
deoxyspergualin 9, 295
depression 169, 265–6
dexamethasone 266
DHPG (ganciclovir) 206
dialysis 157–8, 168
diazepam 189
divided attention 176
donation see living organ donation; organ donation
donor ambivalence 49–52
donor decision-making 46–9
donor motives 43–6
doxepin 268
droperidol 282
drug abuse, cognitive impairment and 169–70
drug-free state 14
drugs
absorption 188–9
hepatic metabolism 189–92
mechanisms of action 9
organ insufficiency effects 187–8, 192
see also specific drugs
dyslexia 170, 178
efficiency 172
elderly patients see geriatric patients
end stage liver disease 214
end stage renal disease (ESRD) 157–8
endothelins 260
endothelial cell (E)-selectin 265
enoxacin 207
episodic memory 177
erythromycin 193, 200, 202
estradiol 267
ethical issues 239
alcoholism and 217–18
anencephalic infants 242–3
Index

criteria for death 241–2
dangerous donors 249–50
defetal donors 244–5
idea of a gift 252–3
justification for transplantation 240–1
living healthy donors 245–7
organ markets 247–9
social justice 249
symbolic concerns 251–2
xenotransplantation 250–1
executive cognitive functions 174

family members
pediatric patients 276–7
perceived burdens of the transplantation experience 122–4
quality of life studies 124–7
role changes 123, 126
fetal donors 244–5
Finger Tapping Speed Test 166
FK506 200–2, 292, 293
fluconazole 202
fluid intelligence 176
fluoxetine 192, 193, 200, 202, 268
fluvoxamine 200, 202, 268
gabapentin 187, 189, 191
ganciclovir 206
gentamicin 208
geriatric patients 146–8
quality of life studies 148–60
heart transplantation 148–53
kidney transplantation 157–60
lung transplantation 153
glucocorticoids 265
γ-glutamyl-transferase (GGTP) 225
glucuronidation 189
graft rejection see rejection
graft-versus-host disease (GVHD) 2–3, 10, 298–9
Grooved Pegboard 166
growth hormone 260
haloperidol 195, 204, 267, 268, 282
Halstead Reitan Battery 166, 167, 180
Hamilton-Anxiety (HAM-A) score 266
Hamilton-Depression (HAM-D) score 266
health, definition of 68
heart failure 192
heart transplantation
alcoholic cardiomyopathy and 216, 220
alcohol-related morbidity and mortality 230–1
post-transplantation issues 230–1
ethical issues
living healthy donors 247
symbolic concerns 251, 252–3
pediatric patients 275, 276
psychosocial selection criteria 27–9
quality of life studies 86–97
comparisons with healthy samples 119–20
comparisons with other similarly ill samples 116–19
geriatric patients 148–53
methodologic issues 120–1
pre- to post-transplantation improvement 111–15
refusal rates 29–30
heart–lung (H–L) transplantation
pediatric patients 275
quality of life studies 96–7
comparisons with healthy samples 119–20
comparisons with other similarly ill samples 116–19
methodologic issues 120–1
pre- to post-transplantation improvement 111–15
hepatic isoenzymes 192–6
hepatitis-C 206
herpesvirus infections 205
High-Risk Alcoholism Relapse (HAR) scale 221–2
host-versus-graft (HVG) interaction 10
human leukocyte antigens (HLAs) 3, 11
5-hydroxytryptamine (5HT) 267, 269
immediate memory 177
immunity
cell-mediated 7–9
diabetes of 266–7
endocrine regulators of 266–7
psychiatric disorders and 265–6
similarities of immune system with nervous system 256–8
stress and 263–5
see also psychoneuroimmunology
immunologic barrier
one-way paradigm 1–9
clinical bone marrow transplantation 3
clinical organ transplantation 3–9
graft-versus-host disease (GVHD) 2–3
rejection 2
tolerance 2
two-way paradigm 9–16
bone marrow transplantation 15–16
whole-organ transplantation 9–15
immunosuppression 6; see also drugs
intelligence 175–6
α-interferon 206–7
interleukins 257, 265
intestinal transplantation 295–6
intracellular adhesion molecule (ICAM) 265
IQ scores 175–6
islet cell transplantation 296–7
Karnofsky Index of Functional Impairment 110
ketanserine 267
ketoconazole 189, 193, 200, 207
kidney donation
donor ambivalence 50
donor decision-making 47, 48–9
ethical issues 245–6
outcomes 53–60
kidney transplantation
pediatric patients 275, 276
psychosocial selection criteria 27–8, 29
quality of life studies 71–85
comparisons with healthy samples 119–20
comparisons with other similarly ill samples 116–19
geriatric patients 157–60
methodologic issues 120–1
pre- to post-transplantation improvement 111–15
refusal rates 29–30
KorsakoV syndrome 177
language capacity 177–8
leukocyte chimerism 10, 11–13, 14
lithium 188, 204, 269
liver
drug metabolism and 187–8, 189–92
hepatic isoenzymes 192–6
liver donation outcomes 61–2
liver transplantation
alcoholic cirrhosis and 215–16, 218–20
alcohol relapse 223–4, 228
monitoring post-transplant alcoholic use 224–6
patient selection criteria 218–20
post-transplant alcohol-related morbidity and mortality 228–9
post-transplant survival 222–3
predictors of post-transplant alcohol use 226–8
sober requirements 218–19
pediatric patients 275–6
psychosocial selection criteria 27–9
quality of life studies 98–103
comparisons with healthy samples 119–20
comparisons with other similarly ill samples 116–19
geriatric patients 154–7
methodologic issues 120–1
pre- to post-transplantation improvement 112–15
refusal rates 29–30
living organ donation 42
ethical issues 245–7
dangerous donors 249–50
organ markets 247–9
postdonation issues 52–62
bone marrow donation outcomes 60–1
kidney donation outcomes 53–60
liver donation outcomes 61–2
predonation psychosocial issues 43–52
donor ambivalence 49–52
donor decision-making 46–9
donor motives 43–6
use of non-related living donors 290
see also organ donation
long term memory 177
lorazepam 189, 268
lung transplantation
pediatric patients 275
quality of life studies 96–7, 111–15
comparisons with healthy samples 119–20
comparisons with other similarly ill samples 116–19
geriatric patients 153
methodologic issues 120–1
Luria Nebraska Neuropsychological Battery 166, 167
lymphokines 256–7
major histocompatibility complex (MHC) graft-versus-host disease and 2–3
malingering 171
Medical Outcomes Study (MOS) 110
memory 177
6-mercaptopurine (6-MP) 6
metadopromide 268
methylphenidate 188, 189, 269
metronidazole 207
mexetine 193
microchimerism 10
midazolam 192
Millon Behavioural Health Inventory 36
Mini-Mental State examination 36
minitransplant models 7
Minnesota Multiphasic Personality Inventory (MMPI) 31, 263
monoclonal antibodies (MAs) 9
monocyte chemoattractant protein (MCP-1) 265
morphine 189
Index

morphine 6-glucuronide 189
motivation, cognition and 171
mycophenolate mofetil 204–5, 292, 293–4
natural killer (NK) cell activity 263
nefazodone 200, 202
neurodevelopmental disorder 170
neurokinins 261, 262
neuroleptic agents 268
neuropsychology, graft rejection and 267
neuropsychological tests 165, 170, 173
computer interactive evaluation 180–1
ecologically valid assessment 180
see also cognitive deficit
neuropsychology 173
change associated with organ transplantation 181–2
nitric oxide synthase (NOS) 262, 265
Norbeck Social Support Questionnaire 31
notorflaxacin 207
Nottingham Health Profile (NHP) 110
OKT3 202–3
olanzapine 191, 194, 195
organ donation
 donor motives 43–6
 financial incentives 291
 increasing public awareness 288–9
 presumed consent 290–1
 use of minority requesters for donor recruitment 289
 use of non-heart-beating donors 289–90
 use of non-related living donors 290
 widening donor criteria 289
 see also living organ donation; specific organs
organ insufficiency 187–8, 192
organ markets 247–9
organ transplantation 3–15
 cognitive development and 182
 justification for 240–1
 neuropsychologic change 181–2
 with total body irradiation 3–6
 see also pediatric transplantation
organ–system interactions 174
oxazepam 189, 268
pancreas transplantation 296–7
 quality of life studies 82–5
 comparisons with healthy samples 119–20
 comparisons with other similar ill samples 116–19
 methodologic issues 120–1
 pre- to post-transplantation improvement 111–15
 panic disorder 266
paroxetine 192, 193, 268
patient selection 249
alcoholism and 217–22
ethics and policies 217–18
heart transplantation 220
liver transplantation 218–20
selection instruments 220–2
sobriety requirements 218–19
geriatric patients 147
medical issues 21–3
pediatric patients 279–80
prioritization 21–2
see also psychosocial screening
Peabody Individual Achievement Test 180
pediatric transplantation 275–84
development issues 277–8
epidemiology 275–6
family issues 276–7
post-transplant follow-up 282–4
pre-transplantation evaluation 279–80
responses of staff 278
transplantation hospitalization 281–2
waiting 280–1
penicillins 207
perception 178–9
persistent vegetative state (PVS) 242
phenobarbital 200
phenothiazines 268
pentolamine 267
phenytoin 188, 189, 200
physical fitness, cognition and 171
Pittsburgh Initial Neuropsychological Test System (PINTS) 167
post-traumatic stress disorder (PTSD) 266
prednisone 6, 204, 294
presumed consent 287, 290–1
procedural memory 177
Profile of Mood States (POMS) 110
progesterone 267
prolacitin 260, 267, 268
pseudodementia 169
psychomotor integration 179
psychoneuroimmunology (PNI) 255
behavioral aspects of psychimmune interaction 263
clinical effects of psychotropic medications 268–9
endocrine regulators of immunity 266–7
psychiatric disorders and immunity 265–6
psychoneuroimmunology communication 258–62
stress and immunity 263–5
psychopathology
cognition and 168–71
see also cognitive deficit

© Cambridge University Press
www.cambridge.org
Psychosocial Adjustment to Illness Scale (PAS) 36, 110, 152
Psychosocial Assessment of Candidates for Transplantation (PACT) 30–1, 32–5, 220–1
psychosocial issues 121; see also living organ donation
psychosocial screening 23–38
Americans with Disabilities Act and evaluation process 25
instruments 30–1
standardized psychological tests 31–7
rationale 23–5
refusal rates 29–30
selection criteria 25–9
quality of life (QOL) 67–8
bone marrow transplant recipients 104–8
comparisons with healthy samples 119–20
comparisons with other similarly ill samples 116–19
families of transplantation recipients 122–7
perceived burdens of transplantation experience 122–4
heart transplant recipients 86–97
geriatric patients 148–53
heart–lung transplant recipients 96–7
improvement from pre- to post-transplantation 111–15
kidney transplant recipients 70–85
geriatric patients 157–60
liver transplant recipients 98–103
geriatric patients 154–7
lung transplant recipients 96–7
geriatric patients 153
measurement 68–70
methodologic issues 120–1
pancreas transplant recipients 82–5
quinidine 189
quinolones 207–8
rapamycin (RPM) 9, 293, 294
reading capacity 178
rejection 2
following drug discontinuation 14–15
neuropsychology and 267
renal transplantation see kidney transplantation
Rey–Osterrieth Complex Figure Test 166
rheumatoid arthritis 266
rifampin 200
risperidone 195
RS-61443 292, 293–4
screening, cognitive dysfunction 166
selective serotonin reuptake inhibitors (SSRIs) 188, 268–9
semantic memory 177
serotonin see 5-hydroxytryptamine
sertraline 192, 200, 202, 268, 269
short term memory 177
short-gut syndrome 188–9, 295
intestinal transplantation 295–6
Sickness Impact Profile (SIP) 110, 151
small bowel transplants (SBTs) 296
Spitzer Q-L Index 110
State-Trait Anxiety Inventory (STAI) 110
steroids 265, 299
stress, immunity and 263–5
substance P (SP) 261, 262
survival rates
alcoholism and post-liver transplantation survival 222–3
pre-transplantation survival 216–17
geriatric patients
heart transplantation 148–53
kidney transplantation 159
liver transplantation 154–7
lung transplantation 153
pediatric transplantation patients 276
Symbol Digit Modalities Test 166
Symptom Checklist-90 (SCL-90) 31–6, 110
systemic lupus erythematosus (SLE) 266–7
T lymphocytes 256
tacrolimus 9, 200–2, 292, 293
thyroid-stimulating hormone (TSH) 260
tolerance 2
induction of 288, 297–9
total body irradiation (TBI) 3–6
total parenteral nutrition (TPN) 295
Trailmaking Test 166
Transplant Evaluation Rating Scale (TERS) 31, 220–1
tricyclic antidepressants 188, 193, 268
trifluoperazine 268
trimethoprim 200
trolley problem 240
tumor necrosis factor (TNF) 257
valproic acid 193
vascular adhesion molecule (VCAM) 265
vasoactive intestinal peptide (VIP) 261–2
waiting lists 21–2, 249
pediatric patients and 280–1
see also patient selection
Wechsler Adult Intelligence Scale 175
Wechsler Memory Scale 167
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wernicke-Korsakoff syndrome</td>
<td>169</td>
</tr>
<tr>
<td>Wide Range Achievement Test</td>
<td>180</td>
</tr>
<tr>
<td>working memory</td>
<td>177</td>
</tr>
<tr>
<td>xenotransplantation</td>
<td>250–1, 287, 291–2</td>
</tr>
<tr>
<td>zero-order kinetics</td>
<td>192</td>
</tr>
<tr>
<td>Zung Depression Inventory</td>
<td>110</td>
</tr>
</tbody>
</table>